29 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA
PRAX-628 Phase 1 study showed consistent safety profile and target engagement
10-K
s9us02iq915i88srcp
17 Mar 21
Annual report
8:33am
10-K
EX-10.3
lxu vz4itw
17 Mar 21
Annual report
8:33am
10-Q
vsftbj88dqfm
23 Nov 20
Quarterly report
4:16pm
424B4
gbk fzfwwpicic3db
16 Oct 20
Prospectus supplement with pricing info
4:02pm
S-1/A
EX-10.1
aaaxapew6l13fq7
9 Oct 20
IPO registration (amended)
6:09am
S-1/A
zq5a6l9zab9 ibf9x
9 Oct 20
IPO registration (amended)
6:09am
S-1
EX-10.2
th89tvbwocfjp
25 Sep 20
IPO registration
5:19pm